TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01399684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m\^2) intravenous (IV) bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m\^2) intravenous (IV) bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folinic acid
Description: Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEGF0444A
Description: Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
Study: NCT02271737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training HC/VHSG, Health Education, and Supportive Supervision
Description: 1. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
Study: NCT02790047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A non-re-breathing face mask with conical-PEP device
Description: Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A home-base exercise program
Description: Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~1. Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~2. Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale \< 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~3. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A home-base exercise program
Description: Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~1. Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~2. Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale \< 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~3. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education include~1. Knowledge of COPD disease~2. Smoking status and smoking cessation~3. Medication correctly~4. Self dyspnea management~5. Basic nutrition for COPD
Study: NCT00544115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Study: NCT02790047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Health education include~1. Knowledge of COPD disease~2. Smoking status and smoking cessation~3. Medication correctly~4. Self dyspnea management~5. Basic nutrition for COPD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ฺBreathing strategies for self secretion clearance
Description: Using a modified active cycle breathing technique (mACBT) include~1. Control breathing~2. Pursed lip breathing (PLB)~3. Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~4. Force expiratory technique (FET) with low to medium lung volume~5. Huffing or coughing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ฺBreathing strategies for self secretion clearance
Description: Using a modified active cycle breathing technique (mACBT) include~1. Control breathing~2. Pursed lip breathing (PLB)~3. Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~4. Force expiratory technique (FET) with low to medium lung volume~5. Huffing or coughing
Study: NCT00544115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Study: NCT02790047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The medication following the COPD GOLD guidelines (2015)
Description: Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~1. Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~2. Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~3. Xanthine derivative (sustained release theophylline)~4. Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~5. Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~6. Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~7. Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)
Study: NCT00544115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total-body irradiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total-body irradiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total-body irradiation
Study: NCT00695292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=4 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: sunitinib 25 mg orally (PO) daily after initial chemotherapy
Study: NCT02759172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention
Description: Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
Study: NCT01033032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Phase I: dose-escalating portion with the starting dose of amrubicin at 90mg/m\^2 IV q21 days. Dose escalations are as follows:~DL2 - 100mg/m\^2; DL3 - 110mg/m\^2; and DL4 - 120mg/m\^2. All cycles are q21 days~Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days
Study: NCT04172259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin liposome
Description: PLD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CTX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: CTX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: H

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: DOC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: DOC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: EPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: P

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: P

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-albumin
Description: albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
Study: NCT04030390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Fatigue
Description: Maximal cycling effort for 30s (Wingate modified)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: time-matched task (sitting on the bike without pedalling)
Study: NCT03831360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Hatha yoga for depressed adolescents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT
Description: Group cognitive behavioral therapy for depressed adolescents
Study: NCT04693832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5inD
Description: Interactive Mobile Application which is includes five different game (mandala, puzzle, tetris, music, breath exercise)
Study: NCT00661609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4877
Description: Intravenous (IV)25mg/weekly
Study: NCT04852562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified radical endoscopic sinus surgery
Description: Modified radical endoscopic sinus surgery was performed to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: functional endoscopic sinus surgery
Description: Full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
Study: NCT03428113

Intervention type: OTHER
Intervention: Bladder Volume Measurement bladder scanner RN
Description: Measure Urine Volume with Bladder Scanner by RN

Intervention type: OTHER
Intervention: Bladder Volume Measurement bladder scanner RN
Description: Measure Urine Volume with Bladder Scanner by RN

Intervention type: OTHER
Intervention: Bladder Volume Measurement Ultrasound APRN
Description: Measure Urine Volume with Point of Care Ultrasound by APRN

Intervention type: OTHER
Intervention: Bladder Volume Measurement Ultrasound APRN
Description: Measure Urine Volume with Point of Care Ultrasound by APRN

Intervention type: OTHER
Intervention: Bladder Volume Measurement bladder scanner APRN
Description: Measure Urine Volume with Bladder Scanner by APRN

Intervention type: OTHER
Intervention: Bladder Volume Measurement bladder scanner APRN
Description: Measure Urine Volume with Bladder Scanner by APRN

Intervention type: OTHER
Intervention: Bladder Volume Measurement Ultrasound MD
Description: Measure Urine Volume with Point of Care Ultrasound by MD

Intervention type: OTHER
Intervention: Bladder Volume Measurement Ultrasound MD
Description: Measure Urine Volume with Point of Care Ultrasound by MD

Intervention type: OTHER
Intervention: Intermittent Straight Catheterization
Description: Measure Urine Volume with Intermittent Straight Catheterization

Intervention type: OTHER
Intervention: Intermittent Straight Catheterization
Description: Measure Urine Volume with Intermittent Straight Catheterization
Study: NCT04254198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TERTULIAS structured dialogue peer support groups
Description: TERTULIAS will involve structured dialogue groups using the model developed and tested by the investigators through their preliminary research. Each group will have 10 women and will meet weekly for two hours over a 12-month period. Group meetings will be conducted in Spanish, led by a team of two FMI facilitators. Facilitation will use the structured dialogue approach. In the last two months of each cohort, participants will be invited to write their own stories or recipes, or produce poetry or art representing their experience to share with the group. These contributions will be gathered and reproduced in booklet form and each participant will receive a copy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Modified Attention Placebo Control (MAPC)
Description: MAPC participants will receive a phone call every other month from the project coordinator to document that their contact information is up to date, to remind them that they are in the study and to tell them that the study is continuing. Survey data and hair samples will be gathered from them at baseline and 12 months
Study: NCT03008863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Study: NCT01180751

Intervention type: RADIATION
Group type: OTHER
Intervention: [18F]-Fluorodeoxyglucose
Description: With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
Study: NCT00526812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 744
Description: Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 744 injection
Description: Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
Study: NCT01566695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: 300 mg daily, days 1 to 21 of each 28-day treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportiv Care (BSC)
Description: BSC included and was not limited to packed RBC (packed red blood cell \[pRBC\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportiv Care (BSC)
Description: BSC included and was not limited to packed RBC (packed red blood cell \[pRBC\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
Study: NCT04181827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-68284528
Description: Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 4 mg will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg/day (10mg/day for participants \>75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants \>75 years of age) in DPd treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 1800 mg will be administered SC.
Study: NCT00617695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: 5mg nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02790047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The medication following the COPD GOLD guidelines (2015)
Description: Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~1. Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~2. Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~3. Xanthine derivative (sustained release theophylline)~4. Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~5. Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~6. Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~7. Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)
Study: NCT00003926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Patients receive oral busulfan every 6 hours on days -8 to -6.
Study: NCT01397396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Three times daily inspiratory muscle training (2x30 breaths) at an intensity of \>50% Pi,max

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Three times daily inspiratory muscle training (2x30 breaths) at an intensity of \>50% Pi,max
Study: NCT01683617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills and relaxation training with new technologies